Otonomy Receives FDA Clearance of Investigational New Drug Application for Tinnitus Product Candidate, OTO-311
October 05, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Oct. 5, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Reports Phase 2b Topline Data for OTO-104 in Meniere's Disease
May 21, 2015 16:05 ET
|
Otonomy, Inc.
Narrowly missed primary endpoint of reduction in vertigo frequency during Month 3 following treatment compared to a one month baseline period, p = 0.067
Achieved statistical significance on...
Otonomy Reports First Quarter 2015 Financial Results and Provides Corporate Update
May 12, 2015 16:01 ET
|
Otonomy, Inc.
SAN DIEGO, May 12, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Completes Enrollment in Phase 2 Clinical Trial for AuriPro(TM) in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes
May 07, 2015 07:00 ET
|
Otonomy, Inc.
SAN DIEGO, May 7, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy to Present at Two Upcoming Investor Conferences
May 06, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, May 6, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Appoints George Morrow to Board of Directors
April 30, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, April 30, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy to Present AuriPro(TM) Phase 3 Results at American Society of Pediatric Otolaryngology Conference
April 21, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, April 21, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Completes Enrollment of OTO-104 Multiple-Dose Safety Study in Meniere's Disease Patients
April 20, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, April 20, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...